Ginkgo Bioworks Holdings (DNA)

Currency in USD
9.100
-0.190(-2.05%)
Real-time Data·

DNA Earnings

Latest Release
Nov 06, 2025
EPS / Forecast
-1.45 / -0.09
Revenue / Forecast
38.84M / 99.94M
EPS Revisions
Last 90 days
Release Date
Period End
EPS
/Forecast
Revenue
/Forecast
EPS Surprise %
Revenue Surprise %
Reaction
09/2025-1.45/-0.0938.84M/99.94M-1,511.11%-61.14%Free Sign Up
06/2025-1.1/-0.149.6M/86.73M-1,000%-42.81%Free Sign Up
03/2025-1.68/-0.0648.32M/47.45M-2,700%+1.83%Free Sign Up
12/2024-2/-0.05843.85M/50.19M-3,330.53%-12.63%Free Sign Up
09/2024--/-0.068--/46.01M----Free Sign Up
06/2024-0.11/-0.0856M/43.14M-37.5%+29.81%Free Sign Up
03/2024-0.08/-0.0837.94M/46.37M0%-18.18%Free Sign Up
12/2023-0.11/-0.134.76M/42.5M-10%-18.21%Free Sign Up
09/2023-0.16/-0.0955.43M/48.08M-77.78%+15.29%Free Sign Up
06/2023-0.09/-0.0980.6M/71.5M0%+12.73%Free Sign Up

All numbers in

Ginkgo Bioworks Holdings Earnings Call Summary for Q3/2025

  • Ginkgo Bioworks reported Q3 2025 cell engineering revenue down 61% YoY to $29 million, with total revenue at $38 million; stock fell 2.5% before recovering 2.24% in aftermarket trading
  • Cash burn reduced by 75% to $28 million compared to Q3 2024, with cash position at $462 million; company restructured Google Cloud contract, eliminating over $100 million in commitments
  • Management set full-year 2025 revenue guidance at $167-$187 million, projecting a 2030 revenue mix of 80% tools and 20% services
  • Strategic pivot toward autonomous labs and AI implementation to control lab robotics, with CEO Jason emphasizing these technologies as crucial for reducing R&D costs and driving future growth
Last Updated: 2025-11-06, 05:46 p/m
Read Full Transcript

FAQ

What Is Ginkgo Bioworks's Earnings Per Share (TTM)?

The Ginkgo Bioworks EPS (TTM) is -6.213.

How Did Ginkgo Bioworks React to the Company's Latest Earnings Report?

Ginkgo Bioworks reported a -1,000% EPS surprise and a -42.81% revenue surprise, comparing the latest report against analyst forecasts. The stock price changed by -22.780%, reflecting the market's response to the earnings results.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.